Coronavirus Update: FDA Tries To Control J&J’s Vaccine, Extended Use Of Paxlovid
The FDA has also moved to limit use of J&J’s COVID-19 vaccine amid reports of rare but dangerous blood clots, while Regeneron highlighted efforts to get approval for REGEN-COV in its Q1 earnings.
You may also be interested in...
Novavax’s COVID-19 Shot Finally Authorized In US, But Could Miss Out Again On Bivalent Booster
A protein-based vaccine for COVID-19 reaches the US at last, but Novavax looks set miss out once again as the fall deadline for BA.4/5 variant-targeting vaccines approaches.
J&J’s Gorsky Offers Leadership Lessons As He Gets Set To Advise Apple
After 34 years of seeing and shaping Johnson & Johnson’s future, executive chair Alex Gorsky has recently joined Apple’s board of directors. At a recent event, he shared lessons for future leaders while unraveling some of the thinking behind decisions taken as chair and CEO
Coronavirus Update: Moderna’s Omicron Vaccine Study Successful, But Data Draw Skepticism
AstraZeneca also published efficacy data for Evusheld in patients with mild-to-moderate COVID-19, while Pfizer is investing $120m in expanding its Paxlovid manufacturing footprint in Michigan.